Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Stomach Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

Laparoscopic D2 lymphadenectomy plus CME will be performed for the treatment of patients assigned to this group.

Laparoscopic D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.

Laparoscopic D2 lymphadenectomy plus CME

Laparoscopic D2 lymphadenectomy

Jianping Gong, M.D.,Ph.D.

Radical gastrectomy for gastric cancer with D2 lymph node dissection has been widely applied in advanced gastric cancer. However,for most patients,tumor local-regional recurrence has been proven unavoidable.

Recently, many clinical studies have proved that some cancer cells and cancer nodes exist in the mesogastrium which can be hardly removed by conventional radical gastrectomy with D2 lymphadenectomy. It is suggested that Complete mesogastrium excision (CME) is imperative and should be added to D2 lymphadenectomy in order to reduce the risk of local recurrence.

Thus, the comparison of short-term and long-term outcome between laparoscopic D2 lymphadenectomy plus complete mesogastrium excision and conventional laparoscopic D2 lymphadenectomy for locally advanced gastric cancer based on a well designed randomized controlled trial is needed.

In this trial, patients and the follow-up staff are masked to the treatment allocation.

Study on Laparoscopic D2 Lymphadenectomy Plus Complete Mesogastrium Excision（D2+CME）for Advanced Gastric Cancer

Prospective Randomized Controlled Trial of Laparoscopic D2 Lymphadenectomy Plus Complete Mesogastrium Excision（D2+CME）vs. Laparoscopic D2 Lymphadenectomy for Advanced Gastric Cancer

Positive rate of cancer cells from intraperitoneal wash samples after gastrectomy

3-years disease-free survival of the enrolled patients

Time to first ambulation, flatus, liquid diet, soft diet, and duration of hospital stay. The amount of abdominal drainage and blood transfusion are also recorded.

The early postoperative complication and mortality are defined as the event observed within 30 days after surgery, while the time frame for late complication is the period from postoperative day 31th to the end of month 36th.

* 3-year overall survival rate \[ Time Frame: 36 months \] \[ Designated as safety issue: No \]
* 3-year recurrence pattern \[ Time Frame: 36 months \] \[ Designated as safety issue: No \]

Recurrence patterns are classified into five categories at the time of first diagnosis: locoregional, hematogenous, peritoneal, distant lymph node, and mixed type.

3-years overall survival of the enrolled patients

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study on Laparoscopic D2 Lymphadenectomy Plus Complete Mesogastrium Excision（D2+CME）for Advanced Gastric Cancer	NCT01978444	Gastric Cancer	Laparoscopic D2... Laparoscopic D2...	18 Years - 75 Years	Huazhong University of Science and Technology
Study on Laparoscopic D2 Lymphadenectomy Plus Complete Mesogastrium Excision（D2+CME）for Advanced Gastric Cancer	NCT01978444	Gastric Cancer	Laparoscopic D2... Laparoscopic D2...	18 Years - 75 Years	Huazhong University of Science and Technology

Spots Global Cancer Trial Database for complete mesogastrium excision